{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/giant-cell-arteritis/background-information/complications/","result":{"pageContext":{"chapter":{"id":"bd2e22a0-2e56-5c05-9b4e-9953cc1765f9","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field 4b7d5195-0522-495e-af88-64e30148da87 --><h2>What are the complications?</h2><!-- end field 4b7d5195-0522-495e-af88-64e30148da87 -->","summary":"","htmlStringContent":"<!-- begin item 138837b7-bf06-4fb5-9c35-8446b066e646 --><!-- begin field 8c1520b5-77e3-46b9-a8fa-646d296458ad --><p><strong>Inflammation in the walls of medium- and large-sized arteries can lead to ischaemic complications such as:</strong></p><ul><li class=\"MsoNormal\"><strong>Loss of vision</strong><ul><li>Total or partial loss of vision may occur in up to 30% of people with giant cell arteritis (GCA).</li><li>One UK study (n = 271) based in a rheumatology setting found that 17% of people with GCA reported irreversible visual loss [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2011</a>].</li><li>A small observational study (n = 136) in people with biopsy-proven GCA reported that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Salvarani, 2005</a>]:<ul><li>Visual symptoms (including amaurosis fugax and diplopia) developed in 41 people (30.1%).</li><li>Partial or total vision loss occurred in 26 people (19.1%).</li><li>Vision loss developed before corticosteroid therapy in 25 of the 26 people who developed vision loss.</li></ul></li><li>Immediate treatment with high dose glucocorticoids reduces the risk of permanent visual loss.</li></ul></li><li><strong>Large artery complications</strong><ul><li>Large artery complications include aortic aneurysm, aortic dissection, large artery stenosis, and aortic regurgitation.</li><li>Between 10 and 20% of people with GCA may develop aortic aneurysm; aortic dissection is less common.</li><li>A population-based study over 50 years (median follow up 7.6 years) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Nuenninghoff, 2003</a>], identified large artery complications in 27% of 168 people with GCA. Aortic aneurysm or aortic dissection occurred in 18%, usually in the thoracic aorta (about 60%). Large artery stenosis occurred in 13%.</li></ul></li><li><strong>Cardiovascular disease</strong><ul><li>Cardiovascular disease (such as myocardial infarction, heart failure, stroke, and peripheral arterial disease) is more common in people with GCA.<ul><li>The reported prevalence of stroke in people with GCA varies from 1–10%. A meta-analysis (n = 17,919) reported a pooled risk ratio of cerebrovascular accident in patients with GCA versus non-GCA controls of 1.40 (95% CI: 1.27 to 1.56) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Ungprasert, 2016a</a>].</li><li>Peripheral artery disease (PAD) — a meta-analysis (n = 9789 people with GCA and 236,728 controls) looking at the association between GCA and risk of PAD reported a pooled risk ratio of PAD in people with GCA compared with those without of 1.88 (95% CI 1.04 to 3.41) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Ungprasert, 2016b</a>].</li></ul></li></ul></li><li><strong>Other complications include:</strong><ul><li>Scalp necrosis, peripheral neuropathy, depression, confusion, encephalopathy, and deafness.</li><li>Adverse effects from long-term corticosteroid treatment (for example weight gain, bruising, osteoporosis and fractures, and diabetes).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Hazleman, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Salvarani, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Weyand, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">De Smit, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Buttgereit, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Prior, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Riambau, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lazarewicz, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Turesson, 2019</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Lyons, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mackie, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/giant-cell-arteritis/references/\">Mollan, 2020</a>]</p><!-- end field 8c1520b5-77e3-46b9-a8fa-646d296458ad --><!-- end item 138837b7-bf06-4fb5-9c35-8446b066e646 -->","topic":{"id":"7eefe727-da7a-5ac5-a30a-dadcb4a4de90","topicId":"922f2e2a-90b2-4d8e-8df9-97f686e2dd9c","topicName":"Giant cell arteritis","slug":"giant-cell-arteritis","lastRevised":"Last revised in September 2020","chapters":[{"id":"28844a63-ce71-58a4-ac10-fb8f990a2ace","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ffc44fb-e6ab-5564-afaf-41f6ec23ae59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d9822672-70ac-5f30-a37c-163c926d69f9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8b641dad-e801-5f07-a15f-837c9e204ae5","slug":"changes","fullItemName":"Changes"},{"id":"b6663d8f-4d43-5493-b6ea-21be0eeae0f0","slug":"update","fullItemName":"Update"}]},{"id":"fbf9fbe8-db19-571e-9da9-58c8a33c3a25","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4a198ad6-17e2-5c80-a074-90f34f9ef1b7","slug":"goals","fullItemName":"Goals"},{"id":"a77ffdda-deba-58f0-9fec-65219eeb836f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d0979f67-3177-527b-add9-89f384b45f07","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c79d9855-b433-5fba-b27d-0999158ea93d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"941fce5c-cd66-5a8b-94ed-bcdf176a7c54","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e4b575e0-3a70-5c29-afb2-b56f7ba46307","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a1c8cdf0-c725-5fb8-889a-3531e77f7aeb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ea4258e9-d463-5d81-ac84-d12cda80042f","slug":"definition","fullItemName":"Definition"},{"id":"cfe98d94-f2b6-58e5-828a-449fb49d3b2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bd2e22a0-2e56-5c05-9b4e-9953cc1765f9","slug":"complications","fullItemName":"Complications"},{"id":"0c5a3725-06fd-5f2f-8aae-4f12da09ec7d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4ce95be1-65d5-5341-a648-8f3418d06670","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c5043d32-5bcd-5396-a271-5864a6d96e74","slug":"suspecting-giant-cell-arteritis","fullItemName":"Suspecting giant cell arteritis"},{"id":"e8c3752d-f9fb-5624-a000-60653edb83ac","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"95e6b3e6-ba05-5b56-8edc-9571fe816995","fullItemName":"Management","slug":"management","subChapters":[{"id":"ecd920ae-cdc1-5314-ba21-3936f06fc825","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c0f0c8dc-11b9-52b8-ba73-a9c6e75e1731","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4e1c5dd9-0908-56f2-91a3-604ea1f9e73d","slug":"oral-prednisolone","fullItemName":"Oral prednisolone"}]},{"id":"5a8fb527-3c07-5253-86eb-d10fc0d5b656","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ff1b1a4d-96ab-5f26-82ea-b4b059ac602f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"627bf4b4-8b65-59ac-8e48-1f7ac20afa3c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"403ae553-2865-56af-9e95-a012c674b4de","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17c8d522-4e76-5f45-aa32-83ed694272f1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bb85fa5d-a667-5361-b411-a3837f26bdc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1f292226-0f24-56c9-983b-c8fa1738c13f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e1a018ae-4d22-516e-8a99-d688c0d3dda6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a1c8cdf0-c725-5fb8-889a-3531e77f7aeb","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}